Table 3. Autonomic and neurohormonal profile in CFS–POTS and non-CFS–POTS.
Non-CFS POTS | CFS-POTS | Controls | |||||
---|---|---|---|---|---|---|---|
Test | Value | n | Value | n | P value | Value | n |
Orthostatic stress test | |||||||
Supine | |||||||
SBP (mmHg) | 104±3 | 17 | 108±2 | 30 | 0.385 | 100±2 | 22 |
DBP (mmHg) | 67±2 | 17 | 67±2 | 30 | 0.963 | 65±2 | 22 |
HR (beats/min) | 75±3 | 17 | 73±1 | 30 | 0.495 | 62±2 | 22 |
10 min standing | |||||||
SBP (mmHg) | 109±4 | 15 | 113±4 | 28 | 0.509 | 100±3 | 22 |
DBP (mmHg) | 72±2 | 15 | 73±2 | 28 | 0.755 | 69±2 | 22 |
HR (beats/min) | 115±6 | 15 | 122±3 | 28 | 0.244 | 85±2 | 22 |
Total standing time (min) | 21±2 | 17 | 20±2 | 30 | 0.902 | 27±2 | 22 |
ΔHR at maximal tolerance (beats/min)* | 40±4 | 17 | 51±3 | 30 | 0.030 | 26±3 | 22 |
Valsalva manoeuvre† | |||||||
Early phase II ΔSBP (mmHg) | −24±4 | 17 | −24±3 | 27 | 0.838 | −14±3 | 21 |
Late phase II ΔSBP (mmHg)‡ | 11±2 | 17 | 18±3 | 27 | 0.041 | 10±2 | 21 |
Phase II ΔHR (beats/min) | 37±4 | 17 | 42±3 | 27 | 0.642 | 25±3 | 21 |
Phase IV overshoot ΔSBP (mmHg) | 31±5 | 17 | 36±3 | 30 | 0.298 | 12±3 | 21 |
Valsalva manoeuvre ratio | 1.95±0.41 | 17 | 2.01±0.06 | 30 | 0.580 | 1.62±0.07 | 21 |
Cold pressor ΔSBP (mmHg)† | 20±2 | 17 | 20±2 | 29 | 1.000 | 20±3 | 20 |
LFRRI (ms2) | 371±92 | 17 | 564±97 | 30 | 0.293 | 921±161 | 22 |
HFRRI (ms2) | 322±109 | 17 | 338±58 | 30 | 0.598 | 1372±321 | 22 |
LFRRI/HFRRI | 2.0±0.3 | 17 | 2.3±0.2 | 30 | 0.406 | 1.1±0.2 | 22 |
LFSBP (mmHg2) | 4.8±1.0 | 17 | 6.3±0.7 | 30 | 0.019 | 3.5±0.6 | 22 |
Plasma noradrenaline (pg/ml) | |||||||
Supine | 173±27 | 17 | 203±27 | 30 | 0.232 | 189±15 | 22 |
Upright | 779±131 | 17 | 635±51 | 30 | 0.587 | 388±18 | 22 |
*HR changes (ΔHR) from supine to standing at the time of maximal orthostatic tolerance.
†BP and HR responses are given as the change (Δ) compared with baseline.
‡BP recovery from early to late phase II of the Valsalva manoeuvre.